 |
| Date | Title | | | 07/27/10 | Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010| SAN DIEGO, July 27, 2010 /PRNewswire via COMTEX/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Wedbush Securities Life Sciences Best Ideas MAC: Management Access Conference in New York on Tuesday, August 3, 2010 at 10:35 a.m. ET / 7:35 a.m. PT. Alex Casdin, vice president, finance of Amylin Pharmaceuticals, will provide a corporate overview.
The presentation will be webcast live through the "Investors" section of Amylin's corporate Web site at www.amylin.com, and ... |
|  | | 07/21/10 | Amylin Pharmaceuticals Reports Second Quarter Financial Results|
Year-to-Date Non-GAAP Operating Loss of $11.2 Million Improves by 74% Compared to 2009
Data Presented at ADA Further Demonstrated Safety and Efficacy Profiles of BYDUREON and BYETTA
SAN DIEGO, July 21, 2010 /PRNewswire via COMTEX/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended June 30, 2010. The Company reported total revenue of $164.4 million for the quarter ended June 30, 2010, which includes net product sales of $162.5 million. Net l... |
| | | 07/14/10 | Amylin Pharmaceuticals to Webcast Second Quarter Results| SAN DIEGO, July 14, 2010 /PRNewswire via COMTEX/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the second quarter of 2010 on Wednesday, July 21, 2010 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the second quarter of 2010.
The call will be webcast live through the "Investors" section of Amylin's... |
| | | 06/26/10 | Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010| Study Showed Improvements Compared to Lantus(R)
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study comparing the effect of long-term treatment with either BYETTA(R) (exenatide) injection or Lantus(R) (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell fu... |
| |
|
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
